Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) in Patients With Advanced Gastric Cancer

Inclusion Criteria: * Age over 18 years old * Histologically or cytologically documented gastric adenocarcinoma * Performance status (ECOG scale): 0-2 * Life expectancy ≥ 3 months * No previous treatment(including: radiotherapy,chemotherapy and immunotherapy) * Prior systemic therapy (for instance, cytotoxic chemotherapy or active/passive immunotherapy) for adjuvant or neoadjuvant treatment for non-metastatic (M0) disease has been completed within 6 months prior to initiation of study treatment. * WIth Measurable Target lesion * Patients should sign a written informed consent before study entry Exclusion Criteria: * History of hypersensitivity to fluoropyrimidines, S-1, oxaliplatin or the ingredients product * Inadequate hematopoietic function: WBC≦5,000/mm3; ANC≦2,000/mm3; Platelet≦100,000/mm3 * Inadequate organ function which is defined as below: Total bilirubin \>2 pper limit of normal range (ULN); ALT / AST \> 2.5 upper limit of normal range (ULN) (\>5.0 x ULN if hepatic metastasis); serum creatinine \> 2 upper limit of normal range (ULN); * Symptomatic peripheral neuropathy ≥ NCI CTC AE grade 1; * Receiving a concomitant treatment with other fluoropyrimidines or fluorocytosine; * Pregnancy or lactation women, or women with suspected pregnancy or men unless using a reliable and appropriate contraceptive method; * Mental status is not fit for chemotherapy therapy presence of serious concomitant illness which might be aggravated by study medication; * History of ventricular arrhythmia or congestive heart failure; * Active cardiac disease e.g. decompensate myocardial infarction within the 6-month period preceding entry into the study; * Significant co-morbid medical conditions, including, but not limited to, Chronic obstructive pulmonary disease, interstitial pneumonia ,pulmonary heart failure, renal failure, hepatic failure, haemorrhagic peptic ulcer, mechanical, paralytic or poor control diabetes